The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast CancerMartin Filipits, Harald Trapl, Christian Fesl et al.|Clinical Cancer Research|2014Cited by 219
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)Christian F. Singer, Michael Gnant, Georg Pfeiler et al.|European Journal of Cancer|2020Cited by 52
Role of pertuzumab in the treatment of HER2-positive breast cancerMichael Hubalek, Christian Marth, Christine A. Brantner|Breast Cancer Targets and Therapy|2012Cited by 20
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34Rupert Bartsch, Christian F. Singer, Georg Pfeiler et al.|British Journal of Cancer|2021Cited by 16
Clinical applications of next‐generation sequencing‐based <scp>ctDNA</scp> analyses in breast cancer: defining treatment targets and dynamic changes during disease progressionEva Valentina Klocker, Michael Gnant, Samantha O. Hasenleithner et al.|Molecular Oncology|2024Cited by 15